Managing diabetic dyslipidemia: Beyond statin therapy

Cardiovascular disease is a significant cause of morbidity and mortality in patients with diabetes mellitus. The lipid profile of type 2 diabetes mellitus is characterized by increased triglycerides (TGs), decreased high-density lipoprotein cholesterol (HDL-C), increased very low density lipoprotein...

Full description

Saved in:
Bibliographic Details
Published in:Current diabetes reports 2009-02, Vol.9 (1), p.11-17
Main Authors: Neeli, Hemanth, Gadi, Ram, Rader, Daniel J.
Format: Article
Language:English
Subjects:
Cholesterol, HDL - blood
Cholesterol, LDL - blood
Cholesterol, LDL - drug effects
Diabetes
Diabetes Complications - therapy
Diabetes Mellitus, Type 2 - blood
Diabetes Mellitus, Type 2 - drug therapy
Diabetic Angiopathies - drug therapy
Diabetic Angiopathies - epidemiology
Diabetic Angiopathies - mortality
Dyslipidemias - drug therapy
Humans
Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use
Hypertriglyceridemia - blood
Hypoglycemic Agents - therapeutic use
Hypolipidemic Agents - therapeutic use
Lipids - blood
Lipids - physiology
Lipoproteins, VLDL - blood
Medicine
Medicine & Public Health
Niacin - therapeutic use
PPAR alpha - agonists
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Cardiovascular disease is a significant cause of morbidity and mortality in patients with diabetes mellitus. The lipid profile of type 2 diabetes mellitus is characterized by increased triglycerides (TGs), decreased high-density lipoprotein cholesterol (HDL-C), increased very low density lipoproteins (VLDLs), and small, dense low-density lipoprotein particles, the combination of which is highly atherogenic. In diabetic patients, current treatment guidelines target low-density lipoprotein cholesterol (LDL-C) ≤ 100 mg/dL with statins. In patients with elevated TGs, non-HDL-C is considered a secondary target of therapy. Despite the use of statin therapy in diabetes, a significant number of fatal and nonfatal coronary heart disease (CHD) events still occur, indicating the need to target other modifiable risk factors for CHD, including high TGs and low HDL-C.
ISSN:1534-4827
1539-0829
DOI:10.1007/s11892-009-0004-y